Market Closed -
Xetra
16:35:46 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
9.235
EUR
|
+0.82%
|
|
-30.35%
|
-56.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,473
|
4,950
|
7,444
|
2,696
|
3,765
|
1,637
|
-
|
-
|
Enterprise Value (EV)
1 |
3,614
|
4,949
|
7,099
|
2,485
|
3,765
|
1,476
|
1,471
|
1,260
|
P/E ratio
|
92.2
x
|
757
x
|
32.7
x
|
-15.4
x
|
-45.3
x
|
67.5
x
|
17
x
|
13.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.78
x
|
9.88
x
|
12
x
|
3.59
x
|
4.82
x
|
1.85
x
|
1.55
x
|
1.36
x
|
EV / Revenue
|
8.1
x
|
9.88
x
|
11.5
x
|
3.31
x
|
4.82
x
|
1.67
x
|
1.39
x
|
1.05
x
|
EV / EBITDA
|
29.3
x
|
46.4
x
|
66.2
x
|
24.4
x
|
56.7
x
|
9.88
x
|
5.72
x
|
3.9
x
|
EV / FCF
|
332
x
|
-91.1
x
|
2,155
x
|
114
x
|
-
|
-92.3
x
|
13.2
x
|
5.7
x
|
FCF Yield
|
0.3%
|
-1.1%
|
0.05%
|
0.88%
|
-
|
-1.08%
|
7.58%
|
17.5%
|
Price to Book
|
7.25
x
|
6.86
x
|
5.44
x
|
2.27
x
|
-
|
1.41
x
|
1.32
x
|
1.2
x
|
Nbr of stocks (in thousands)
|
150,653
|
163,476
|
175,162
|
176,703
|
176,936
|
177,290
|
-
|
-
|
Reference price
2 |
23.05
|
30.28
|
42.50
|
15.26
|
21.28
|
9.235
|
9.235
|
9.235
|
Announcement Date
|
26/03/20
|
25/03/21
|
12/04/22
|
12/05/23
|
24/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
446.4
|
500.9
|
618
|
751.4
|
781.4
|
884
|
1,056
|
1,205
|
EBITDA
1 |
123.1
|
106.6
|
107.3
|
101.7
|
66.35
|
149.4
|
257.1
|
323.1
|
EBIT
1 |
62.59
|
48.52
|
41
|
20.85
|
-26.63
|
45.95
|
141.5
|
196.7
|
Operating Margin
|
14.02%
|
9.69%
|
6.63%
|
2.77%
|
-3.41%
|
5.2%
|
13.39%
|
16.32%
|
Earnings before Tax (EBT)
1 |
56.56
|
25.81
|
237
|
-154
|
-80.59
|
1.165
|
97.36
|
148.5
|
Net income
1 |
38.07
|
6.252
|
215.5
|
-175.7
|
-83.91
|
10.36
|
73.87
|
113
|
Net margin
|
8.53%
|
1.25%
|
34.87%
|
-23.38%
|
-10.74%
|
1.17%
|
6.99%
|
9.37%
|
EPS
2 |
0.2500
|
0.0400
|
1.300
|
-0.9900
|
-0.4700
|
0.1368
|
0.5428
|
0.6920
|
Free Cash Flow
1 |
10.89
|
-54.35
|
3.294
|
21.75
|
-
|
-16
|
111.5
|
221
|
FCF margin
|
2.44%
|
-10.85%
|
0.53%
|
2.89%
|
-
|
-1.81%
|
10.55%
|
18.34%
|
FCF Conversion (EBITDA)
|
8.85%
|
-
|
3.07%
|
21.4%
|
-
|
-
|
43.36%
|
68.41%
|
FCF Conversion (Net income)
|
28.61%
|
-
|
1.53%
|
-
|
-
|
-
|
150.95%
|
195.64%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/03/20
|
25/03/21
|
12/04/22
|
12/05/23
|
24/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
231
|
159.7
|
187.1
|
164.7
|
172.2
|
336.9
|
173.9
|
240.7
|
170.3
|
383.8
|
196.3
|
250.1
|
208.1
|
204.8
|
218
|
233.7
|
EBITDA
|
47.27
|
-
|
37.21
|
18.9
|
14.7
|
33.64
|
10.96
|
57.05
|
-
|
26.1
|
24.11
|
16.14
|
-
|
-
|
-
|
-
|
EBIT
|
18.92
|
-
|
14.94
|
0.463
|
-3.77
|
-3.307
|
-13.53
|
37.69
|
-36.29
|
-
|
-12.19
|
-7.687
|
-
|
-
|
-
|
-
|
Operating Margin
|
8.19%
|
-
|
7.99%
|
0.28%
|
-2.19%
|
-0.98%
|
-7.78%
|
15.66%
|
-21.31%
|
-
|
-6.21%
|
-3.07%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-17.84
|
-
|
-24.34
|
-
|
-43.36
|
-17.52
|
-20.44
|
-
|
-29.92
|
-24.02
|
-10.96
|
-12.18
|
-8.312
|
-0.662
|
Net income
1 |
-
|
-
|
-31.48
|
-73.24
|
-27.94
|
-101.2
|
-47.28
|
-27.2
|
-14.93
|
-28.83
|
-38.96
|
-16.13
|
-22.88
|
-23.37
|
-20.88
|
-15.36
|
Net margin
|
-
|
-
|
-16.83%
|
-44.48%
|
-16.22%
|
-30.03%
|
-27.19%
|
-11.3%
|
-8.77%
|
-7.51%
|
-19.85%
|
-6.45%
|
-11%
|
-11.41%
|
-9.58%
|
-6.58%
|
EPS
|
-
|
-
|
-0.2000
|
-0.4100
|
-0.1600
|
-0.5700
|
-0.2700
|
-0.1500
|
-0.0800
|
-
|
-0.2200
|
-0.0900
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/08/20
|
12/11/21
|
12/04/22
|
11/05/22
|
11/08/22
|
11/08/22
|
09/11/22
|
12/05/23
|
29/08/23
|
29/08/23
|
08/11/23
|
24/04/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
141
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
0.67
|
345
|
212
|
-
|
161
|
166
|
377
|
Leverage (Debt/EBITDA)
|
1.149
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
10.9
|
-54.4
|
3.29
|
21.8
|
-
|
-16
|
112
|
221
|
ROE (net income / shareholders' equity)
|
8.45%
|
1.04%
|
20.5%
|
-13.7%
|
-
|
2.75%
|
7.28%
|
9.27%
|
ROA (Net income/ Total Assets)
|
3.89%
|
0.47%
|
11.7%
|
-7.82%
|
-
|
-0.48%
|
1.16%
|
2.06%
|
Assets
1 |
978.7
|
1,322
|
1,849
|
2,246
|
-
|
-2,137
|
6,367
|
5,492
|
Book Value Per Share
2 |
3.180
|
4.420
|
7.810
|
6.720
|
-
|
6.540
|
7.000
|
7.720
|
Cash Flow per Share
2 |
0.2800
|
0.2900
|
0.7300
|
1.150
|
-
|
0.1900
|
0.7600
|
0.9400
|
Capex
1 |
31.3
|
99.1
|
119
|
181
|
-
|
149
|
122
|
130
|
Capex / Sales
|
7.02%
|
19.78%
|
19.25%
|
24.13%
|
-
|
16.82%
|
11.59%
|
10.81%
|
Announcement Date
|
26/03/20
|
25/03/21
|
12/04/22
|
12/05/23
|
24/04/24
|
-
|
-
|
-
|
Last Close Price
9.235
EUR Average target price
24.7
EUR Spread / Average Target +167.46% Consensus |
1st Jan change
|
Capi.
|
---|
| -56.60% | 1.75B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|